Celltrion USA - Olean Times Herald

Press Releases

Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Convergence 2024

Celltrion USA

November 18, 2024

JERSEY CITY, N.J. , Nov. 18, 2024 /PRNewswire/ -- Celltrion today presented additional data from a Phase III randomized controlled trial (RCT)for CT-P...

Press Releases

ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)

Celltrion USA

October 31, 2024

JERSEY CITY, N.J. , Oct. 31, 2024 /PRNewswire/ -- Celltrion USA announced today that, through continued partnership with key PBMs and health plans, th...

Press Releases

Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA®â¯ (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting

Celltrion USA

October 29, 2024

JERSEY CITY, N.J. , Oct. 29, 2024 /PRNewswire/ --Celltrion USA today announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBER...

Olean Times Herald

Get in touch with Olean Times Herald

Submit Content

Advertise

Subscribe